ストックスクリーナーアプリを入手
5.08
4.51%
-0.24
アフターアワーズ：
5.08
前日終値:
$5.32
開ける：
$5.34
24時間の取引高:
418.64K
Relative Volume:
0.42
時価総額：
$403.07M
収益：
-
当期純損益:
$-119.87M
株価収益率:
-2.8066
EPS:
-1.81
ネットキャッシュフロー:
$-109.90M
1週間 パフォーマンス:
-10.41%
1か月 パフォーマンス:
+8.32%
6か月 パフォーマンス:
-50.49%
1年 パフォーマンス:
-46.53%
1日の値動き範囲:
$5.04
$5.59
1週間の範囲:
$4.52
$5.83
52週間の値動き範囲:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
名前
Oric Pharmaceuticals Inc
セクター
電話
(650) 388-5600
住所
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
5.08 | 403.07M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-31 | 開始されました | Wells Fargo | Overweight |
| 2024-09-06 | 開始されました | Stifel | Buy |
| 2024-02-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 開始されました | Wedbush | Outperform |
| 2023-03-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Perform |
| 2022-04-04 | アップグレード | Citigroup | Neutral → Buy |
| 2022-03-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-03-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-13 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-06 | アップグレード | Citigroup | Neutral → Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-19 | 開始されました | Citigroup | Neutral |
| 2020-05-19 | 開始されました | Guggenheim | Buy |
| 2020-05-19 | 開始されました | JP Morgan | Overweight |
| 2020-05-19 | 開始されました | Jefferies | Buy |
すべてを表示
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
Q2 EPS Forecast for ORIC Pharmaceuticals Raised by Analyst - MarketBeat
ORIC Pharmaceuticals (ORIC) Receives Increased Price Target from H.C. Wainwright | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (ORIC) Price Target Raised by Analyst | ORIC Stock News - GuruFocus
Wedbush Boosts Earnings Estimates for ORIC Pharmaceuticals - Defense World
Price T Rowe Associates Inc. MD Has $10.45 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Schonfeld Strategic Advisors LLC Takes $5.85 Million Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Oppenheimer Cuts ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target to $12.00 - MarketBeat
Cantor Fitzgerald Reiterates "Overweight" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Issues Quarterly Earnings Results - MarketBeat
1,732,571 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Bought by Boxer Capital Management LLC - MarketBeat
Ratio Review: Analyzing ORIC Pharmaceuticals Inc (ORIC)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
MetLife Investment Management LLC Has $336,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wells Fargo & Company MN - Defense World
ORIC Pharmaceuticals Reports Q1 2025 Progress and Plans - TipRanks
ORIC Pharmaceuticals (ORIC) Target Price Lowered by Oppenheimer | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (ORIC) Receives Reiterated "Overweight" Rat - GuruFocus
Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating - marketscreener.com
Oppenheimer Revises Price Target for ORIC Following Quarterly Re - GuruFocus
Barclays PLC Grows Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reaffirmed at HC Wainwright - Defense World
ORIC Pharmaceuticals Inc Reports Q1 2025 Earnings: EPS Misses Estimate at -0.51, Revenue Remains at $0 Million - GuruFocus
Oric Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oric Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J Partnership, Reports 5 Clinical Readouts Coming in Cancer Drug Pipeline - Stock Titan
Invesco Ltd. Grows Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (ORIC) Rating Reiterated at HC Wainwright & Co. | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
(ORIC) Long Term Investment Analysis - news.stocktradersdaily.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oncology Biotech ORIC Issues Major Equity Package: 32,400 Options Plus RSUs for New Talent - Stock Titan
An analyst sees good growth prospects for ORIC Pharmaceuticals Inc (ORIC) - Sete News
Market Watch: ORIC Pharmaceuticals Inc (ORIC)’s Noteworthy Drop, Closing at 5.57 - DWinneX
Is ORIC Pharmaceuticals Inc (ORIC) worth investing in despite its overvalued state? - uspostnews.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Legal & General Group Plc - Defense World
ORIC Pharmaceuticals Inc’s Shares Reel: -51.58% Quarterly Revenue Decline Amid 401.98M Market Cap - investchronicle.com
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
79,900 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Acquired by Natixis - MarketBeat
ORIC-944 shows promise in prostate cancer treatment - Investing.com
ORIC Pharmaceuticals Highlights Promising Preclinical Data on OR - GuruFocus
ORIC® Pharmaceuticals Presents Preclinical Data to Support the P - GuruFocus
ORIC-944 shows promise in prostate cancer treatment By Investing.com - Investing.com South Africa
ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer - marketscreener.com
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by Silverarc Capital Management LLC - MarketBeat
Diadema Partners LP Invests $1.73 Million in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Average PT from Analysts - MarketBeat
Oric Pharmaceuticals Inc (ORIC) 財務データ
収益
当期純利益
現金流量
EPS
Oric Pharmaceuticals Inc (ORIC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
115,615 |
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):